Sucampo Pharma (SCMP) Tops Q3 EPS by 2c; Raises Outlook

Sucampo Pharma (NASDAQ: SCMP) reported Q3 EPS of $0.27, $0.02 better than the analyst estimate of $0.25. Revenue for the quarter came in at $61.3 million versus the consensus estimate of $58.05 million.

GUIDANCE:

Sucampo Pharma sees FY2017 EPS of $1.10-$1.15, versus the consensus of $1.01. Sucampo Pharma sees FY2017 revenue of $250-255 million, versus the consensus of $234.5 million.

For earnings history and earnings-related data on Sucampo Pharma (SCMP) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Wolfspeed (WOLF) Misses Q4 EPS by 174c; Offers Guidance
• Is the global equity rally broadening? UBS weighs in